Premium
Commentary: Identifying individualized predictions of response in ADHD pharmacotherapy – a commentary on Rodrigues et al. (2020)
Author(s) -
Farhat Luis C.,
Bloch Michael H.
Publication year - 2021
Publication title -
journal of child psychology and psychiatry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.652
H-Index - 211
eISSN - 1469-7610
pISSN - 0021-9630
DOI - 10.1111/jcpp.13374
Subject(s) - atomoxetine , methylphenidate , psychology , context (archaeology) , aripiprazole , autism , attention deficit hyperactivity disorder , psychiatry , autism spectrum disorder , risperidone , tics , clinical psychology , psychotherapist , schizophrenia (object oriented programming) , paleontology , biology
In this issue, Rodrigues et al. (2020) present a systematic review with meta‐analyses that reports the efficacy of five treatments for children with attention‐deficit hyperactivity disorder symptoms in the context of autism spectrum disorder – (a) methylphenidate; (b) atomoxetine; (c) guanfacine; (d) aripiprazole; and (e) risperidone. In this commentary, we highlight the contrast between the scarce evidence base of treatment for ADHD in the context of autism and other subpopulations, such as tic disorders and intellectual disability, and the extensive evidence base of treatment for ADHD in general. The commentary weighs about the conundrum clinicians face of whether to rely on the limited evidence base of treatment for ADHD in subpopulation, or to derive conclusions from the larger body of evidence of treatment for ADHD in general. The commentary also discusses potential avenues for future research to address this clinical problem.